DMD Gene Therapy

Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease that affects 1 in every 3,500 to 5,000 male neonates worldwide. It is caused by mutations in the gene encoding the protein dystrophin. These genetic changes emerge as developmental delays and, in more severe types of DMD, limb weakness, loss of indep...

Duchenne Muscular Dystrophy (DMD) is a rare disorder, but it is one of the most common genetic conditions, affecting roughly 1 in every 3,500 male births worldwide. It is usually observed between the ages of three and six. Duchenne Muscular Dystrophy signs and symptoms include pelvic muscles atrophy, followed by in...

AZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi ...